EffRx Pharmaceuticals SA is a commercial-stage functionally integrated pharmaceutical company, based in Switzerland, that develops and commercializes niche & orphan medicines in Europe. EffRx aims to be the preferred accelerator for late clinical & regulatory development, approval, valorization of niche medicines in Europe and Switzerland.
EffRx’s competence and success is proven by the development, launch and lucrative expansion of Binosto® in a highly competitive European market. Our lead commercialized product, Binosto® for the treatment of osteoporosis is marketed in the US, Europe, selected MENA and Asian countries. Binosto® offers a number of potential advantages over traditional therapeutic approaches.
EffRx has an experienced Board of Directors and Management Team with proven development and commercialization success within pharmaceutical and biotechnology companies.